Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Inflectra

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background: Although Inflectra, biosimilar infliximab, has been approved by the EMA since September 2013 for all licensed… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
2017
2017
Background In the light of scientific data, the medical and pharmaceutical community (rheumatology, gastroenterology, internal… 
2017
2017
Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy for… 
2016
2016
Background The first infliximab (IFX) biosimilar (CT-P13) in Europe is marketed as two brand names, Inflectra (IFT) and Remsima… 
2016
2016
Background Biosimilars of infliximab have been recently introduced in clinical practice in inflammatory bowel disease (IBD) when… 
2016
2016
Introduction Switching from an established biologic to a biosimilar to save costs was considered likely to be ‘inappropriate and… 
2016
2016
The criterion adopted by EMA for approving biosimilars is that these agents must be supported by a comparability exercise; at the… 
  • table 1
2016
2016
Introduction CT-P13 is the biosimilar Infliximab approved for use in Europe and it is marketed in the UK in two brand names… 
2016
2016
  • Nature Biotechnology
  • 2016
  • Corpus ID: 205268225
455 Remicade in Europe, saw sales of the drug drop to $1.79 billion last year from $2.3 billion in the previous year. In a… 
2016
2016
  • 2016
  • Corpus ID: 160018782
WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. • Increased risk of… 
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5